Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

Phase 1 Completed 27 enrolled Alligator Bioscience AB

NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to assess the safety and tolerability of increasing doses of ATOR-1017 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

Timeline

Start: 2019-12-03
Primary completion: 2023-03-29
Completion: 2023-03-29

Outcome

Met primary endpoint

release “The primary objective of the study to investigate the safety and tolerability of ATOR-1017 at therapeutic doses has been successfully met.” alligatorbioscience.se ↗

Publications

Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4. Epub 2024 Jan 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVUNZEKIBART	Monoclonal antibody	—	Intravenous